TWI275393B - Use of bisphosphonates for pain treatment - Google Patents
Use of bisphosphonates for pain treatment Download PDFInfo
- Publication number
- TWI275393B TWI275393B TW090129419A TW90129419A TWI275393B TW I275393 B TWI275393 B TW I275393B TW 090129419 A TW090129419 A TW 090129419A TW 90129419 A TW90129419 A TW 90129419A TW I275393 B TWI275393 B TW I275393B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- pain
- acid
- substituted
- patent application
- Prior art date
Links
- 229940122361 Bisphosphonate Drugs 0.000 title claims abstract description 48
- 150000004663 bisphosphonates Chemical class 0.000 title claims abstract description 42
- 208000002193 Pain Diseases 0.000 title claims abstract description 32
- 238000011282 treatment Methods 0.000 title claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- -1 bisphosphonate compound Chemical class 0.000 claims description 20
- 208000004454 Hyperalgesia Diseases 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 206010006002 Bone pain Diseases 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 230000005012 migration Effects 0.000 claims description 5
- 238000013508 migration Methods 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 206010053552 allodynia Diseases 0.000 claims description 2
- OVARJRDCUIDTGY-UHFFFAOYSA-N hydroxy-[1-hydroxy-2-(1h-imidazol-3-ium-3-yl)-1-phosphonoethyl]phosphinate Chemical group OP(=O)(O)C(P(O)([O-])=O)(O)C[N+]=1C=CNC=1 OVARJRDCUIDTGY-UHFFFAOYSA-N 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000009545 invasion Effects 0.000 claims 1
- 150000002923 oximes Chemical class 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000005740 tumor formation Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 11
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 229960004276 zoledronic acid Drugs 0.000 abstract description 3
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 abstract description 3
- 230000003574 anti-allodynic effect Effects 0.000 abstract description 2
- 208000027866 inflammatory disease Diseases 0.000 abstract description 2
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010049088 Osteopenia Diseases 0.000 abstract 1
- 230000003502 anti-nociceptive effect Effects 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 19
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 210000000988 bone and bone Anatomy 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 239000002775 capsule Substances 0.000 description 9
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 8
- 208000035154 Hyperesthesia Diseases 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 210000000548 hind-foot Anatomy 0.000 description 7
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000024279 bone resorption Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000007937 lozenge Substances 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 208000006386 Bone Resorption Diseases 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 208000004296 neuralgia Diseases 0.000 description 5
- 208000021722 neuropathic pain Diseases 0.000 description 5
- 210000002997 osteoclast Anatomy 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229920002367 Polyisobutene Polymers 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 230000000423 heterosexual effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- MQFLXLMNOHHPTC-UHFFFAOYSA-N 1-isothiocyanato-9-(methylsulfinyl)nonane Chemical compound CS(=O)CCCCCCCCCN=C=S MQFLXLMNOHHPTC-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 208000037147 Hypercalcaemia Diseases 0.000 description 2
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical group [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 229960002286 clodronic acid Drugs 0.000 description 2
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 239000013530 defoamer Substances 0.000 description 2
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000000148 hypercalcaemia Effects 0.000 description 2
- 208000030915 hypercalcemia disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003791 organic solvent mixture Substances 0.000 description 2
- 229960003978 pamidronic acid Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- PMXAPNNYCFBALB-UHFFFAOYSA-N (1-hydroxy-1-phosphono-3-pyrrolidin-1-ylpropyl)phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCN1CCCC1 PMXAPNNYCFBALB-UHFFFAOYSA-N 0.000 description 1
- RDFHOSXBGDLRQF-UHFFFAOYSA-N (2-anilino-1-phosphono-2-sulfanylideneethyl)phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)C(=S)NC1=CC=CC=C1 RDFHOSXBGDLRQF-UHFFFAOYSA-N 0.000 description 1
- VJSAMRGFQQKFAN-UHFFFAOYSA-N (2-phosphonohydrazinyl)phosphonic acid Chemical compound N(NP(O)(=O)O)P(O)(=O)O VJSAMRGFQQKFAN-UHFFFAOYSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- IGQNITWOOQMZGG-UHFFFAOYSA-M 1-decylpyridin-1-ium;iodide Chemical compound [I-].CCCCCCCCCC[N+]1=CC=CC=C1 IGQNITWOOQMZGG-UHFFFAOYSA-M 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 1
- KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- ZBCYZRSCBGENRI-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid trihydrate Chemical compound O.O.O.OC(=O)CC(O)(C(O)=O)CC(O)=O ZBCYZRSCBGENRI-UHFFFAOYSA-N 0.000 description 1
- LEOCGIQQASUQSI-UHFFFAOYSA-N 3-(didecylamino)propan-1-ol Chemical compound CCCCCCCCCCN(CCCO)CCCCCCCCCC LEOCGIQQASUQSI-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- YAEIVDMBNAGDES-UHFFFAOYSA-N C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(C)NN(CC)CC Chemical compound C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(C)NN(CC)CC YAEIVDMBNAGDES-UHFFFAOYSA-N 0.000 description 1
- KYTWUFXLRDBYGE-UHFFFAOYSA-N CC.OP(=O)OP(O)=O Chemical compound CC.OP(=O)OP(O)=O KYTWUFXLRDBYGE-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 description 1
- 239000013032 Hydrocarbon resin Substances 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000037848 Metastatic bone disease Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PQBAWAQIRZIWIV-UHFFFAOYSA-N N-methylpyridinium Chemical class C[N+]1=CC=CC=C1 PQBAWAQIRZIWIV-UHFFFAOYSA-N 0.000 description 1
- 229920002402 Oppanol® B 100 Polymers 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- VGCUFGXAHRPSNF-UHFFFAOYSA-N [1-amino-2-(1-methylimidazol-4-yl)-1-phosphonoethyl]phosphonic acid Chemical compound CN1C=NC(CC(N)(P(O)(O)=O)P(O)(O)=O)=C1 VGCUFGXAHRPSNF-UHFFFAOYSA-N 0.000 description 1
- VADUXZPJGJBSLQ-UHFFFAOYSA-N [1-hydroxy-3-(1-methylpyridin-1-ium-3-yl)-1-phosphonopropyl]phosphonic acid;hydroxide Chemical compound [OH-].C[N+]1=CC=CC(CCC(O)(P(O)(O)=O)P(O)(O)=O)=C1 VADUXZPJGJBSLQ-UHFFFAOYSA-N 0.000 description 1
- XFDRFWQRYYEEEI-UHFFFAOYSA-N [2-(1h-imidazol-2-yl)-1-phosphonoethyl]phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)CC1=NC=CN1 XFDRFWQRYYEEEI-UHFFFAOYSA-N 0.000 description 1
- FGBXDQWECLPOGZ-UHFFFAOYSA-N [Na].O.O.O.O.O.[Na] Chemical compound [Na].O.O.O.O.O.[Na] FGBXDQWECLPOGZ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 229940042400 direct acting antivirals phosphonic acid derivative Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- KTGBYROLTNECAS-UHFFFAOYSA-L disodium;[2-anilino-1-[hydroxy(oxido)phosphoryl]-2-sulfanylideneethyl]-hydroxyphosphinate Chemical compound [Na+].[Na+].OP([O-])(=O)C(P(O)([O-])=O)C(=S)NC1=CC=CC=C1 KTGBYROLTNECAS-UHFFFAOYSA-L 0.000 description 1
- JFGHPLSPUGOSLV-UHFFFAOYSA-L disodium;[3-(dimethylamino)-1-hydroxy-1-[hydroxy(oxido)phosphoryl]propyl]-hydroxyphosphinate Chemical compound [Na+].[Na+].CN(C)CCC(O)(P(O)(O)=O)P([O-])([O-])=O JFGHPLSPUGOSLV-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000773 effect on pain Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920006270 hydrocarbon resin Polymers 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- WSGCRAOTEDLMFQ-UHFFFAOYSA-N nonan-5-one Chemical compound CCCCC(=O)CCCC WSGCRAOTEDLMFQ-UHFFFAOYSA-N 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003007 phosphonic acid derivatives Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229960000759 risedronic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000012748 slip agent Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 229960005324 tiludronic acid Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
1275393 A7 _ B7 _· 五、發明説明(1 ) 本發明有關一種醫藥組合物及用途,尤其有關一種包括 雙膦酸鹽之醫藥組合物及雙膦酸鹽之新穎治療用途。 雙膦酸鹽廣泛用以於涉及過度或不適當骨吸收之各種良 性及惡性疾病之破骨細胞活性。該等焦磷酸鹽類似物不僅 減少骨架相關事件亦可提供病患臨床效益及改善之存活率 。雙膦酸鹽可避免體内骨吸收;雙膦酸鹽之治療效果已證 明可治療骨質疏鬆症、骨疼痛、骨骼之佩格氏疾病、腫瘤 誘發之高血斜(TIH)且更近來證明可用於骨遷移(BM)及多發 性骨髓瘤(MM)(回顧可參見Fleisch Η 1997雙膦酸鹽之臨床 學,於骨疾病之雙膦酸鹽研究,自實驗室至病患,編輯: Parthenon出版集團,紐約/倫敦,第68-163頁)。雙膦酸鹽抑制 骨再吸收之機制並未完全明瞭且依據雙膦酸鹽研究而多有 變化。雙膦酸鹽已顯示可強烈結合至骨骼之羥磷灰石結晶 ,而降低骨骼轉換(turn-over)及再吸收,降低血液中羥基脯 胺酸或鹼磷酸晦量、及又抑制破骨細胞形成、補充、活化 及活性。近來法呢機二磷酸鹽合成腾(一種膽固醇生合成甲 美里戊酸醋路徑之酵素)已鑑定為含氮雙膦酸鹽之分子標的(回 顧於 Rogers MJ,Gordon S,Benford HL,Coxon FR,Luckman SP,Monkkonen J,Frith JC,2000.雙膦酸鹽之細胞及分子機 制作用,Cancer 88(增補版):2961-2978)0 源自結構破損、骨膜刺激及神經參與之骨骼疼痛為良性 及惡性及轉移性骨疾病之最普遍關聯,且於醫院及社會實 務上造成嚴重問題(Coleman,1997, Cancer 80; 1588-1594) 〇 MM為血漿-細胞惡性病,特徵為骨髓中惡性血漿細胞增 -4- 本紙張尺度適用中關家標準(CNS) A4规格(210X297公爱)— -' 1275393 A7 _B7___ 五、發明説明(2 ) " 殖及累積。主要之臨床結果為伴隨病理破骨及骨骼疼痛之 溶胞骨骼損害。該等損害源自過度骨再吸收,經常導致高 血鈣。雙膦酸鹽已介紹可長期與習知化學療法組合治療MM 。近來顯示雙膦酸鹽如氣多尼酸鹽(clodronate)及帕米多尼 酸鹽(pamidronate)可減少骨架相關事件發生如溶胞骨損害 及病理破骨且可舒緩伴隨之骨疼痛及改善病人生活品質 (Laktinen等人,Lancet 1992,340,1049-1052 ; McCloskey等 人,B.J. Haematol·,1998,100,3 17-325 ;及 Berenson 等人,Ν· Eng· J. Med. 1996,卷 334,第 8期,488-493)。類似效果報導 於以雙膦酸鹽治療之乳癌病患(Hortobagyi GN, Theirault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF,Seaman J, Knight RD.帕米多納於患有乳癌及 溶胞骨遷移之病患中降低骨併發症之效果。Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996; 335:1785-91 ; Kanis JA, Powles T, Paterson AHG,
McCloskey EV,Ashley S·氣多尼酸鹽於患乳癌之女性中減 少骨遷移頻率,Bone 1996; 19:663-7)。 已意外地發現某種雙膦酸鹽於活體動物模型中對疼痛展 現完全且適當之直接減緩效果。例如唑多尼酸(zoledronic acid)已發瑪於慢性發炎及神經病理痛之老鼠模型中逆轉機 械性痛覺過敏,快速發生作用及效率達約100%。另外唑多 尼酸已發現於骨癌疼痛之老鼠模型中減少機械性異痛症及 減少後爪撲打。該等結杲顯示唑多尼酸及類似雙膦酸鹽可 能對疼痛具有直接、快速作用之抗-感受疼痛&抗異痛症活 本紙張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 1275393 A7 -——一 _wr_ 五、發明説日^ 1 一)一" "" ' ———— 性。 依據本發明提供一種對需治療之病患治療疼痛之方法, 包括對病患投與有效量之雙膦酸鹽。 本务明又提供一種雙膦酸鹽製備治療疼痛之醫藥之用途。 本發明又提供一獐雙膦酸鹽用以治療哺乳類與疾病或病 理病況有關之疼痛之用途。 3 :内 本發明尤其可用於舒緩疼痛,亦即除了舒緩處理疾病戈 醫藥病況(其為疼痛肇因)結果而舒緩疼痛以外可直接舒緩疼 …°因此’有利地’本發明提供-種直接止痛或急性治療 疼痛之方法及用途。 較好本發明用於其中使用雙膦酸鹽抑制破骨細胞活性之 疾病及醫藥病況之直接治療疼痛之方法。例如,本發明可 用於直接治療涉及過度或不適當骨質流失之疾病及病況之 疼痛,如不當破骨細胞活性結果引起者。此疾病及病況實 例包含良性疾病及病況如各種原因之骨質疏鬆症、杜德袼 m骨關節炎' ha'齒骨膜疾病;及特収惡性疾病 如與各種癌有關之MM及TIH及BM,如乳癌、前列腺癌、肺 癌、腎癌、卵巢癌或骨癌瘤。通常本發明可用於治療雙膦 酸鹽可使用且遭遇疼痛之其他狀況之疼痛,例如當使用雙 膦酸鹽癒合骨骼破碎、骨壞死或治療彌補術鬆弛。 本發明之用途及方法代表對既有使用雙膦酸鹽預防或抑 制骨遷移或過度骨質再吸收之惡性疾病治療之改良,亦用 以治療發炎疾病如風濕性關節炎及骨關節炎以及所有類型 之骨質疏鬆症及骨疼痛。· -6 - 本纸張尺度適用中國國家標準(CNS) A4規格(210X297公爱) 1275393 A7
因此本發明中,,治療,,代表預防及治癒或舒緩疼痛,尤里 是抗-感受疼痛及抗異痛症疼痛,特別是治療骨疼痛。 因此本發明特定具體例中,本發明提供: 一種對需治療之病患治療骨疼痛之方法,包括對該病患 投與有效量之雙膦酸鹽; 〜 種雙脚S文鹽製備供治療骨疼痛之醫藥之用途;或 一種雙膦酸鹽作為骨疼痛治療劑之用途。 本發明所用之雙膦酸鹽典型上為可舒緩疼痛,尤其是具 有抗-感受疼痛及抗異痛症者,且較好對疼痛具有快速發揮 之活性者〇 因此例如,用於本發明之適宜雙膦酸鹽可包含下列化合 物或其醫藥可接受性鹽或其任何水合物:3-胺基經基丙 院-1,卜二膦酸(帕米多尼酸(p ami dr on ic acid)),如帕米多尼 酸鹽(APD) ; 3-(N,N-二曱基胺基)-1-羥基丙烷」山二膦酸, 如二甲基- APD ; 4-胳基-1-經基丁烧- i,i-二膦酸(歐多尼酸 (alendronic acid)),如歐多尼酸鹽;1·羥基-亞乙炔雙膦酸, 如依多尼酸鹽(etidronate) ; 1-羥基-3-(甲基戊胺基)亞丙炔基 雙膦酸、依班多尼酸(ibandronic acid),如依班多尼酸鹽; 6-胺基-1-羥基己烷-1,1-二膦酸,如胺基己基-BP ; 3-(N-甲 基-N-正戊胺基)-1-羥基丙烷-1,1-二膦酸,如曱基戊基-APD(=BM21.0955) ; 1 -羥基-2-(咪唑-1 -基)乙烷-1,1 -二膦酸 ,如唑多尼酸;1-羥基-2-(3-吡啶基)乙烷-1,1-二膦酸(利沙 多尼酸(risedronic acid)),如利沙多尼酸鹽’包含其N-甲基 吡啶鑌鹽,例如碘化N-曱基吡啶鑌鹽如NE-10244或NE- 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1275393 A7 B7 五、發明説明(5 ) 10446 ; 1-(4-氣苯硫基)甲烷-1,1-二膦酸(惕i多尼酸 (tiludronic acid)),如惕鹵多尼酸鹽;3-[N-(2-苯硫基乙基)-N-甲基胺基]-1-羥基丙烷-l,l-二膦酸;1-羥基-3-(吡咯啶-1-基)丙烷-1,1-二膦酸,如EB 105 3(Leo) ; 1-(N-苯胺基硫羰基 )甲烧-1,1-二膦酸,如FR 78844(Fujisawa); 5-苯曱酿基-3,4-二氫-2H-吡唑-3,3-二膦酸四乙4,如U-81581(普強);1-羥 基-2-(咪唑并[i,2-a]吡啶-3-基)乙烷-1,1-二膦酸,如YM529 ’及1,1- 一氣甲烧-1,1-二膦酸(氣多尼酸(clodronic acid)), 如氣多尼酸鹽。 用於本發明之雙膦酸鹽較好為含氮雙膦酸鹽。就本說明 目的而言,含氮之雙膦酸鹽為除了特徵雙葉雙膦酸鹽(P-Ce P)部分以外又包括含氮側鏈之化合物,例如式I化人物· P(0R)2
Rx--X 1 『)2 〇 其中 X為氫、羥基、胺基、烷醯基或經Ci·4烷基取代之胺基或烷 醯基; R為氫或Cl.4烧基,及
Rx為含有視情況取代之胺基或含氮雜環(包含芳族含氮雜環 )之側鏈, 〈 及其醫藥可接受性鹽及其任何水合物。 特佳含氣雙膦酸鹽為具有含氮雜環側鏈者’最好為芳族含 -8- $紙張尺度適用中g @家標準(Cns) A4規格(210><297公I) ------------ - 1275393 A7
氮雜環。 因此一具體例中 Γ之化合物: 可用於本發明之特佳雙膦酸鹽包括式
II
Het-A-'C—χ* I Γ ff 伽)2 〇 其中 Τ為米坐、噚唑、異碍唑、哼二唑、噻唑、。塞二唑、吡 °疋丨,2,3-二唑、丨,2,4-三唑或苯并咪唑基,其視情況經烷 基、烷氧基、_素,、羥基、羧基、視情況經烷基或烷醯基 取代之月*基或視情況經烧基、硝基、胺基或胺烧基取代之 苄基取代; Α為含1至8個碳原子之直鏈或分支、飽和或不飽和烴基; X為氫原子,視情況經烷醯基或視情況經烷基或烷醯基取 代之胺基取代,及 R為氫原子或(^-4烷基, 及其醫藥可接受性鹽。 另一具體例中,用於本發明之特佳雙膦酸鹽包括式IHb 合物: γ f\ 丨
Het•-g—8中1· por)2 〇 «9- 本紙張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 1275393 A7 B7 五 發明説明(7 、 其中
Het’為經取代或未經取代雜芳族5-員環,係選自咪唑基、 味唾琳基、異嘮唑基、嘮唑基、噚唑啉基、噻唑基、噻唑 琳基、三唾基、碍二唑基及噻二唑基所成之組群,其中該 環可部分氫化且其中該取代基係選自由cN4烷基、Cl 4烷氧 基、笨基、環己基、環己基甲基、鹵素及胺基所成組群之 至少一種基且其中Het兩相鄰烷基取代基可一起形成第二環 Y為氫或CN4烷基; X”為氫、羥基、胺基或經c1-4烷基取代之胺基,及 R為氫或CN4烧基; 以及其醫藥可接受性鹽及其異構物。 又另一具體例中*,用於本發明之特佳雙膦酸鹽包括式ΙΠ 化合物:
訂
其中
Het”為咪唑基、2Η-1,2,3-、1Η-1,2,4-或 4Η·1,2,4-三唾基 、四唑基、·哼唑基.、異哼唑基、哼二唑基、噻唾基或嗔二 唑基,其為未經取代或經低碳烷基、低碳烷氧基、又可經 低碳院基、低碳烧氧基及/或函素單-或二取代之笨美、_芙 、二-低碳烷胺基、低碳烷硫基及/或鹵素C-單·或二-取代, -10- 本紙張尺度適用中國國家標準(CNS) Α4規格(210 X 297公釐) 1275393 A7 __________ B7 ______ 五、發明説明(8 ) 且可在可取代之N-原子經低碳烷基或經又可經低碳烷基、 低碳烧氧基及/或鹵素單-或二取代之苯基-低碳烷基N-取代 ,及 R2為氫、羥基、胺基、低碳烷硫基或鹵素,低碳基含有 達且包含7個C原子, 或其醫藥可接受性鹽。 用於本發明之特4雙膦酸鹽實例為: 2-(1-甲基咪唑-2-基)-1-羥基乙烷-1,1-二膦酸; 2-(1-苄基咪唑基^丨-羥基乙烷-丨,丨·二膦酸; 2 ( 1-曱基σ米。坐-4 -基)-1 -經基乙烧-1,1 -二鱗酸; 1-胺基-2-(1-甲基咪唑-4-基)乙烷-1,1-二膦酸; 1- 胺基-2-(1-苄基咪唑-4·基)乙烷-l,.l-二膦酸; 2- (1-甲基咪唑-2-基)乙烷-1,1-二膦酸; 2-U-苄基咪唑-2-基)乙烷-1,1-二膦酸; 2-(咪唑-1·基)-1-瘂基乙烷-1,1-二膦酸; 2·(咪唑-1-基)乙烷-1,1-二膦酸; 2-(411-1,2,4-二。坐-4-基)-1-經基乙烧-1,1-二鱗酸; 2·(噻唑-2-基)乙烷-1,1-二膦酸; 2-(咪唑-2-基)乙烷-1,1-二膦酸; 2-(2-曱基咪唑-4(5)-基)乙烷-1,1-二膦酸; 2-(2-笨基咪唑-4(5)-基)乙烷-1,1-二膦酸; 2-(4,5-二甲基味吐-1-基)-1-經基乙院-1,1-二膦酸;及 2-(2 -曱基味σ坐-4(5) -基)-1-經基乙烧-1,1-二膦酸; 及其醫藥可接受性鹽。 -11 -
本紙張尺度適用中國國家標準(CNS) A4规格(210X297公釐) 1275393 A7 B7 五、發明説明(9 ) ------ 用於本發明之最佳雙膦酸鹽為2-(咪唑-U基)·^羥基乙 烷1,1-一膦酸(唑多尼酸)或其醫藥可接受性鹽或里任 合物。 八 醫藥可接受性鹽較好為與驗之鹽,宜為衍生自元素週期 表la、lb、na及lib族之金屬鹽,包含鹼金屬鹽如鉀及尤其 納鹽’或驗土金屬Μ ’較好為職㈣,亦可為與氨或有 機胺之銨鹽。 特佳之醫藥可接受性鹽為雙膦酸之一、二、三或四個, 尤其一或兩個酸性氫經醫藥可接受性陽離子,特別是鈉、 _或銨置換者,尤其鈉置換。 極佳類之醫藥可接受性鹽特徵為各膦酸基中具有一個酸 性氫及一個醫藥可接受性陽離子,特別是鈉。 所有上述雙膦酸衍生物均可自文獻得知。包含其製法(例 如參見ΕΡ-Α-5 13760 ,第Π-48頁)。例如3-胺基-1-羥基丙烷_ 1,1-二膦酸如例如USP 3,962,432所述製備,及鈉鹽如usp 4,639,338及4,711,880般製備,及1-經基-2-(咪唾_ι_基)乙燒· 1,1-二膦酸如USP 4,939,130所述般製備。亦可參見USp 4,777,163及 4,687,767。 雙膦酸鹽(後文稱為本發明藥劑)若適宜可以異構物態或 異構物之混合物態使用,一般以光學異構物態使用例如對 映異構物或非對映異構物或幾何異構物,一般為順-反式異 構物。該光學異構物可獲得純對映體及/或消旋體態。 本發明藥劑亦可使用其水合物或包含其他用於其結晶之 溶劑。 -12- 本紙泵尺度適用中國國家標準(CNS) A4規格(210X 297公釐) " --------— 1275393 A7 B7
五、發明説明 本發明藥劑(雙膦酸鹽)較好使用含有治療有效量之活性 成分及視情況與一或多種適於投藥之無機或有機、固體或 液體之醫藥可接受性載體混合之混合物之醫藥組合物態7 此醫藥組合物可為例如供經腸如口服、直腸、氣溶膠吸 入或鼻投藥之組合物,供非經腸道如靜脈内或皮下投藥之 組合物,或供經皮投藥之組合物(如被動或離子透入法)。
較好,醫藥組合物採用口服或非經腸道(尤其靜脈内、動 脈内或經皮)投藥。靜脈内及口服且尤其靜脈内投㈣認為 特別重要。較好該雙膦酸鹽活性《分為非經腸道態,最好 經脈内投藥。 投藥及劑型之特定模.式可藉參與之醫師考慮特定病患, 尤其年齡、體重、生活類型、活動程度、賀爾蒙狀態(如停 經後)及骨礦物質密度(若適當)加以選擇。然而最好雙膊酸 鹽為靜脈内投藥。 訂
本發明藥劑之劑型可視各種因素如活性成分效率及活性 持久性'投藥模《、溫血動物種類及/或溫血動物之性別、 年齡、體重及個別病況而定。 L d 2L為對體%重約75公斤之溫血動物投與自〇·⑻2至 20.0毫克/A斤,尤其〇〇1至1〇〇毫克/公斤之雙膦酸鹽活性 成分之單一劑量。若需要,此劑量亦可分成數次(視情況等 量)部分投藥。 “耄克/公斤’’意指每公斤欲治療哺乳類(包含人類)之毫克 藥物。 上述劑量·單一劑量(較佳)或數次部分劑量-可例如每曰重 13 - 本紙張尺度適用中® ®家標規格_X 297公釐) I275393
複—次’每週-次、每月-次、每三個 -次或每年一次。換言之,§藥組合物 至間歇循環治療之療程投藥。 月一次、每六個月 可依連續每日治療 酸衍生物治療之疾 或骨質疏鬆症所用 膦酸衍生物之劑量 金鈣症或骨質疏鬆 有效抑制骨骼再吸 尼酸及其鹽而言, 10¾克範圍之雙膦 較好,雙膦酸鹽可以與傳統上以雙膦 病如柏哲德疾病、腫瘤誘發之高血^症 相同等級之劑量投藥。換言之,較好雙 類似地為治療柏哲德疾病、腫瘤誘發高 症之治療有效量,亦即較好投藥劑量可 收。例如對較佳之含氮雙膦酸鹽如唑多 可使用約0.5至約20亳克,較好約1至約 酸鹽劑量治療人類病患。 · 單一劑型之調配物較好含有約1%至約90%活性成分,及 不為單一劑型之調配物較好含約01%至約20%活性成分。 單一劑量單位如膠囊、錠劑或糖衣錠含有例如約丨毫克至約 5 00毫克活性成分。 經腸或非經腸道之醫藥製劑為例如單一劑型者如糖衣鍵 、錠劑或膠囊且亦可為小瓶。其藉本身已知方法製備,例 如藉習知混合、造粒、包糖衣、溶解或凍乾製程製備。 例如,口服投藥之醫藥組合物可藉組合活性成分與固體 載體’適當時使所彳于混合物造粒且若需要在添加適當佐劑 於錠劑或糖錠核心後使混合物或顆粒加工。適當載體尤其 為填充劑如糖類例如乳糖、蔗糖、甘露糖醇或山梨糖醇、 纖維素製劑及/或磷酸鈣例如磷酸三鈣或磷酸氫鈣,亦可為 黏合劑如玉米、小麥、稻米或馬鈴薯澱粉、明膠、黃書膠 •14· 1275393 A7 __ B7—_ 五、發明説明(12 ) 、甲基纖維素及/或聚乙烯基吡咯啶酮及若需要之崩解劑如 上述澱粉,亦可為羧甲基澱粉、交聯聚乙烯基吡咯啶酮、 瓊脂或褐藻酸或其鹽如褐藻酸鈉。佐劑尤其為流動調節劑 及潤滑劑如矽酸、滑石、硬脂酸或其鹽如硬脂酸鎂或硬脂 酸鈣及/或聚乙二醇。糖錠核心可具有抗胃酸之適當包衣, 其中可使用視情況含有阿拉伯糠、滑石、聚乙烯基吡咯烷 酮、聚乙二醇及/或二氧化鈦之濃縮糖溶液,或於適當有機 溶劑或溶劑混合物之酊溶液,或為了製得抗胃酸之包衣, 可為適當纖維素製劑之溶液,如乙醯基纖維素酞酸酯或羥 丙基曱基纖維素酞酸酯。可於錠劑或糖錠包衣中添加著色 物質或顏料,例如用於分辨或用於指示不同劑量活性成分 之目的。 其他口服醫藥製,為由明膠製得之乾填充膠囊,亦可為 由月膠及塑化劑如甘油或山梨糖醇製得之軟、密封勝囊。 «亥乾填充之膠囊可含有顆粒態之活性成分,例如與填充劑 如乳糖、黏合劑如澱粉及/或滑劑如滑石或硬脂酸鎂及若適 當之穩定劑之混合物。軟膠囊中,活性成分較好溶於或懸 洋於適當液體中如脂肪油、石蠟油或液體聚乙二醇,其亦 可添加穩定劑。 非經腸道之調配物尤其可為注射流體其以各種方式作用 ,如動脈内、肌肉内、腹膜内、鼻内、皮内、皮下或較好 靜脈内投藥。此流體較好為等張水溶液或懸浮液,其可在 使用珂例如自僅含有活性成分或又含有醫藥可接受載體之 床乾製劑製備。該醫_組合物可殺菌及/或含有佐劑例如保 •15- 本紙張尺度制巾@國家標準(CNS) A4規格(灿X 297公嫠了 1275393 A7 B7 五、發明説明(13 ) 存劑、穩定劑、濕潤劑及/或乳化劑、溶解劑、調節滲透壓 之鹽及/或緩衝劑。 經皮施用之適宜調配物包含有效量之活性成分及載體。 有利之載體包含可吸收醫藥可接受性溶劑以助於通過宿主 皮膚。特徵上,經皮裝置係成繃帶狀,其包括背襯元件、 含化合物及視情況含載體之健存槽、視情況之速率控制障 壁以長期在經控制及既定速率下輸送活性成分通過宿主皮 膚、以及使裝置固定於皮膚之元件。 下列實例說明本發明。 下列實例中,‘‘活性成分”需了解為本發明可使用之上述 任何雙膦酸衍生物。 ’ 實例 复姓1 :含活性成分如帕米多尼酸鈉五水合物作為活性成分 之包衣粒片之膠囊: 核心粒片· - 197.3毫克 52.7毫克 活性成分(研磨) 微晶纖維素(Avicel® PH105) 250.0毫克 +内部包衣: 10.0毫克 2.0毫克 8.0毫克 纖維素HP-M603 聚乙二醇 滑石 本紙張尺度適用中國國家標準(CNS) A4規格(210X 297公釐) 1275393 A7 B7 五、發明説明(14 ) 270.0毫克 +胃酸抗性外包衣: Eurdagit® L30D(固體) 90.0毫克 檸檬酸三乙酉旨 21.0毫克 消泡劑® AF 2.0毫克 水 滑石 7.0毫克 , 390.0毫克 帕米多尼酸二鈉與Avicel® PH105之混合物以水濕潤及捏 合,擠出及形成球型。乾燥粒片接著以由纖維素HP-M 603 、聚乙二醇(?£0)8000及滑石所構成之内包衣及由£11(^8丨1:<1) L3 0D、檸檬酸三乙酯及消泡劑®八?所構成之含水之胃酸抗 性包衣於流體化床中依序包衣。包衣之粒片以滑石粉化及 藉商業膠囊填入機例如HSfliger及Karg填充入膠囊(膠囊大 小0號)。 ϋϋ:含例如1-羥基-2-(咪唑-1-基)乙烷二膦酸作為活 性成分之單片黏著經皮系統: 組成 : 5.0克 3·〇克 9·0克 43.0 克 20.0 克 聚丁烯(PIB) 300(〇ppan〇l Bl,BASF) PIB 35000(〇ppanol BIO, BASF) PIB 1200000 (Oppanol B100, BASF) 氫化烴樹脂(Escorez 5320, Exxon) 1-十二烷基氮雜環庚烷-2-酮 -17- 本紙張尺度適用中國國家標準(CNS) Α4規格(210X 297公釐) 1275393 A7
(Azone,Nelson Res·,Irvine/CA) 100.0 克 活性成分 合計 製備: 上述成分藉輥輪齒輪床一起溶於15〇克特定沸點之石油 餾份100-125。溶液藉塗佈裝置使用3〇〇亳米刮刀片塗佈 至聚酷膜(Hostaphan Kalle),獲得約75克/米2之塗膜。乾 燥(在60°C 15分鐘)後,塗佈矽氧處理之聚酯膜(厚度γ ^ 米,Laufenberg)作為剝除膜。完成之系統使用沖打工2 沖打出5至30cm2大小。完成之系統個別密封於鋁羯紙^ 袋中。 · ’ 二含ΐ·〇毫克凍乾之1-羥基-2_(咪唑·丨—基)乙烷·丨山二 膦酸(其混合之鈉鹽)之小瓶。以i毫升水稀釋後,獲得㈣ 内灌注用之溶液(濃度!毫克/毫升)。 組成: 1 ·〇毫克 46.0毫克 約3.0毫克 1亳升 活性成分(游離二膦酸) 甘露糖醇 擰檬酸三鈉X 2H20 水 · 於1毫升水中,以檸檬酸三鈉x 2H20分散活性成分至1^1 6·〇。接著添加甘露糖醇及溶液凍乾及凍乾物填入小瓶中。 复含溶於水中之例如帕来多尼酸二鈉五水合物作為活 -18- !275393
A7 B7 五、發明説明(16 之溶液(濃度3毫克/ 性成分之安瓿。稀釋後獲得靜脈内灌注 毫升)。 組成: 19·73亳克 250亳克 5毫升 活性成分 (Μ·〇克無水活性成分) 甘露糖醇 注射用水 貫例5雙Α酸鹽於發炎及神經病理^^ 方法 發炎性痛覺過敏
於發炎疼痛之老鼠中檢視機械痛覺過敏。藉RandaU
Sellito技術使用分析計(Ug〇 Basile, Milan)於自然動物中在 左後爪足底注射完全Freund,s完全佐劑(FCA)前測量增加壓 力刺激之爪抽回閥值。24小時後,在(劑量前)接著自投藥或 投與載劑後10分鐘至6小時再度測量爪抽回閥值。依據下式 計算同側爪中逆轉之痛覺過敏。 處置後閥值-處置前閥值 %逆轉=-—-X 100 自然閥值-處置前閥值 神經病理痛覺過敏 藉左坐骨神經部分結紮誘發神經病理疼痛之老鼠模型中 檢視機械痛覺過敏。約14天後,處置前及藥物或載劑投與 後10分鐘至6小時測量結紮(同側)及未結紮(反側)爪兩者之 -19· 本紙張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 1275393 五、發明説明(π ) 手術機械抽回閥严。⑯據下#計算各點之痛㊄過敏 %逆韓=處置後同側閥值-處置前同側閥值 ^ ---— χίοο 處置刖反側閥值-處置前同側閥值 使用6隻動物一組進行所有實驗。現存濃度之藥物溶於蒸 餾水中及隨後於4毫升/公斤之體積於〇9%食鹽水中稀釋供 皮下投藥。所有藥物於塑膠小瓶中調和並保存於暗處。 使用ANOVA重複測量抽回閥值之統計學分析接著進行
Tukey’s HSD測試。效率代表在所用劑量所觀察之痛覺過敏 最大逆轉。 結果 1. 於單側後爪注射完全Freund,sE劑唑多尼酸鹽 0.1毫克/公斤S.C·)誘發之發炎痛覺過敏模型中產生劑 量依存性之機械痛覺過敏逆轉。該效果快速發生,= 30分鐘内達最大逆轉1〇〇%,及投藥後3小時短期内無明 顯活性。 ' 2. 帕米多尼酸鹽(0.03 —丨毫克/公斤s c )及氣多尼酸鹽(〇 % 1〇毫克/公斤S.C.)在逆轉發炎機械痛覺過敏均無效,但 在最高測試劑量產生略減少之爪抽回閥值。 3·於單側部分坐骨神經結紮誘發之慢性神經病理疼痛模型 中,唑多尼酸鹽(0.003-0」亳克/公斤sc)產生中度之 40%機械痛覺過敏逆轉,其在投藥3〇分鐘内達最大。然 而,在最高劑量亦無明顯反側爪抽回閥值斤低。 4·在神經病理疼痛模型中帕米多尼酸鹽(〇 〇3」毫克/公斤 s.c.)僅具弱作用,產生最大20%痛覺過敏逆轉,而氣多尼 本纸張尺度適用中國國家標準(CNS) A4規格(210X297公着) -20- 1275393 ---------------B7 五、發明説 18) "~ '一"一 一~一 酸鹽(0.3-10毫克/公斤s c )則無活性。兩藥物再產生反 側爪抽回閥值些許降低。 5·違等數據顯示嗤多尼酸鹽於老鼠慢性發炎及神經病理疼 痛模型中逆轉機4痛覺過敏。 貝例6隻膦酸鹽於iiji疼痛去g樽型中之效杲 雌性成鼠以脛骨内注射MRMZ-1老鼠乳腺癌瘤細胞(3微升 ,ίο7細胞/毫升)。該等動物逐漸發展機械痛覺過敏、機械 異痛症(對非有害刺激之皮膚敏感性)及後肢拍打,在細胞注 射後1 2-14天開始。自細胞注射當天開始每週3次投與唑多 尼酸(ZOL)(10及30微克/公斤sc),產生完全抑制後爪拍打 及機械異痛症。與載劑處理對照組(其顯示第19天之最大後 爪拍打)相較,給予、交高Z〇L之老鼠在脛骨内細胞注射19天 内未發展任何後爪拍打訊號。然而,當第19天以單一注射 投藥時(1〇〇微克/公斤s.c·),Z0L不具確實效果。相反地, 以嗎啡(1-10毫克/公斤S.C.)急性處理在機械異痛症中產生劑 量依存性降低,及僅在最高劑量,亦具有明顯降低後爪拍 打0 -21 - 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐)' "~ --
Claims (1)
- 正充 A BCD 1275^^〇129419 號專利申 請案 中文申請專利範圍替換本(93年5月) 六、申請專利範圍 1 · 一種用於治療病患疼痛之醫藥組合物,其包含有效量之 雙膦酸鹽,該雙膦酸鹽係式III化合物, 〇 II p(〇h)2 Her—c—C-R2 in 2 fj_2 o 其中 Het” 為咪唑基 ’ 2H-1,2,3-、1H-1,2,4-或 4H-1,2,4-三唑基 ,四唑基,嘮唾基,異嘮唑基,噚二唑基,嘧唑基或噻 二唑基,其為未經取代或經低碳烷基、低碳烷氧基、又 可經低碳烷基、低碳烷氧基及/或_素單-或二取代之苯 基、羥基、二-低碳烷胺基、低碳烷硫基及/或_素之C-單-或二-取代,且為可在可取代之N-原子經低碳烷基或 、起·又可經低〗厌烧基、低碳烧乳基及/或鹵素單-或二取代 之苯基·《低碳烷基之N-取代,及 R2為氫、羥基 '胺基、低碳烷硫基或鹵素,低碳基係含 有最多7個C原子, 或其醫藥可接受性鹽或其水合物。 2*根據申請專利範圍第1項之醫藥組合物,其係用於對病 患進行抗-感受疼痛及抗-異痛症治療。 3.根據申請專利範圍第1項之醫藥組合物,其係用於骨疼 痛之治療。 4·根據申請專利範圍第1項之醫藥組合物,其係用以治療 本紙張尺度適用中國國家標準(CNS) A4規格(210 x 297公釐) 1275393 A8 B8 C8 D8 六、申請專利範圍 與骨質疏鬆症、風濕性關節炎、骨關節炎及腫瘤形成( 如腫瘤生長)、侵入或遷移有關之疼痛。 5.根據申請專利範圍第1項之醫藥組合物,其中該雙膦酸 鹽係1 -羥基-2-(咪唑-1 -基)乙烷-1,1 -二膦酸(唑多尼酸 (zole dr on ic acid))或其醫藥可接受性鹽或水合物。本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0029111.2A GB0029111D0 (en) | 2000-11-29 | 2000-11-29 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI275393B true TWI275393B (en) | 2007-03-11 |
Family
ID=9904112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW090129419A TWI275393B (en) | 2000-11-29 | 2001-11-28 | Use of bisphosphonates for pain treatment |
Country Status (27)
Country | Link |
---|---|
US (2) | US20040063670A1 (zh) |
EP (1) | EP1339411B1 (zh) |
JP (1) | JP2004514696A (zh) |
KR (2) | KR100866025B1 (zh) |
CN (1) | CN1535152A (zh) |
AT (1) | ATE366112T1 (zh) |
AU (2) | AU2002217061B2 (zh) |
BR (1) | BR0115696A (zh) |
CA (1) | CA2427161C (zh) |
CY (1) | CY1106851T1 (zh) |
CZ (1) | CZ301701B6 (zh) |
DE (1) | DE60129242T2 (zh) |
DK (1) | DK1339411T3 (zh) |
ES (1) | ES2287191T3 (zh) |
GB (1) | GB0029111D0 (zh) |
HU (1) | HUP0302556A3 (zh) |
IL (2) | IL155363A0 (zh) |
MX (1) | MXPA03004815A (zh) |
NO (1) | NO20032405D0 (zh) |
NZ (1) | NZ525871A (zh) |
PL (1) | PL204001B1 (zh) |
PT (1) | PT1339411E (zh) |
RU (1) | RU2325913C2 (zh) |
SK (1) | SK287501B6 (zh) |
TW (1) | TWI275393B (zh) |
WO (1) | WO2002043738A2 (zh) |
ZA (1) | ZA200303247B (zh) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8119159B2 (en) | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
PL361909A1 (en) | 2001-02-06 | 2004-10-04 | The Royal Alexandra Hospital For Children | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
US7875597B2 (en) * | 2002-07-24 | 2011-01-25 | New York University | Treatment of spinal mechanical pain |
JPWO2005072746A1 (ja) * | 2004-01-30 | 2007-10-11 | アステラス製薬株式会社 | P2x受容体阻害剤 |
WO2005107751A1 (en) | 2004-05-06 | 2005-11-17 | Merck & Co., Inc. | Methods for treating arthritic conditions in dogs |
KR20070043043A (ko) * | 2004-08-23 | 2007-04-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법 |
JP2009508834A (ja) * | 2005-09-16 | 2009-03-05 | セラマイン リミテッド | ビスホスホネート製剤 |
US7473684B2 (en) * | 2005-09-16 | 2009-01-06 | Selamine Limited | Bisphosphonate formulation |
AU2007235251B2 (en) | 2006-04-07 | 2013-02-07 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
GB0624090D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amine salts |
GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
US8974801B2 (en) | 2006-12-21 | 2015-03-10 | Amphastar Pharmaceuticals Inc. | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate |
ITPA20070034A1 (it) * | 2007-10-30 | 2009-04-30 | Tetrapharm S R L | Bifosfonati geminali, loro preparazione e loro impiego in campo oncologico. |
US7977323B2 (en) | 2007-11-30 | 2011-07-12 | Novartis Ag | C2-C5-alkyl-imidazole-bisphosphonates |
CN102046152A (zh) * | 2008-04-04 | 2011-05-04 | 诺瓦提斯公司 | 含有双膦酸盐的药物组合物 |
WO2009137078A1 (en) | 2008-05-07 | 2009-11-12 | Merrion Research Iii Limited | Compositions of peptides and processes of preparation thereof |
CA2746612A1 (en) * | 2008-12-23 | 2010-07-08 | Novartis Ag | Phenylalkyl-imidazole-bisphosphonate compounds |
US9089484B2 (en) | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
GB201011552D0 (en) * | 2010-07-09 | 2010-08-25 | Smith & Nephew | Adhesive and a method of delivery |
ES2540828T3 (es) | 2010-09-02 | 2015-07-13 | Naturland Magyarország Termelö És Kereskedelmi Kft. | Preparación aplicable por vía peroral que contiene histaminasa de origen vegetal, resistente a pepsina y tripsina y un procedimiento para producirla |
ITNA20100046A1 (it) * | 2010-09-28 | 2012-03-29 | Abbruzzese Saccardi Alberto | Uso di bisfosfonati per la preparazione di formulazioni farmaceutiche per il trattamento dei sintomi associati a dolore neuropatico |
US8802114B2 (en) | 2011-01-07 | 2014-08-12 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
SG10201604653TA (en) * | 2011-12-11 | 2016-07-28 | Recro Pharma Inc | Intranasal dexmedetomidine compositions and methods of use thereof |
US10413561B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
US9789128B2 (en) | 2012-05-14 | 2017-10-17 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9662343B2 (en) | 2012-05-14 | 2017-05-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US20150051175A1 (en) * | 2012-05-14 | 2015-02-19 | Antecip Bioventures Ii Llc | Co-Administration of Steroids and Zoledronic Acid to Prevent and Treat Pain |
US9700570B2 (en) | 2014-05-27 | 2017-07-11 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10413560B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
US9956237B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US9877977B2 (en) | 2012-05-14 | 2018-01-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9949993B2 (en) | 2012-05-14 | 2018-04-24 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US8865757B1 (en) | 2014-05-28 | 2014-10-21 | Antecip Bioventures Ii Llp | Therapeutic compositions comprising imidazole and imidazolium compounds |
PT2849758T (pt) * | 2012-05-14 | 2018-05-09 | Antecip Bioventures Ii Llc | Composições que compreendem o ácido zoledrónico ou compostos relacionados para o alívio da dor inflamatória e estados relacionados |
US10080765B2 (en) | 2012-05-14 | 2018-09-25 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US10092581B2 (en) | 2014-05-15 | 2018-10-09 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US10493085B2 (en) | 2012-05-14 | 2019-12-03 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
US9782421B1 (en) | 2012-05-14 | 2017-10-10 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
US9694023B2 (en) | 2012-05-14 | 2017-07-04 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
US9717747B2 (en) | 2012-05-14 | 2017-08-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US9427403B2 (en) | 2012-05-14 | 2016-08-30 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
US9901589B2 (en) * | 2012-05-14 | 2018-02-27 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US8802658B2 (en) * | 2012-05-14 | 2014-08-12 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
US9795622B2 (en) | 2012-05-14 | 2017-10-24 | Antecip Bioventures Ii Llc | Neridronic acid for treating pain associated with a joint |
US9675626B2 (en) | 2012-05-14 | 2017-06-13 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9956234B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
US9999628B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US10028969B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9867839B2 (en) | 2012-05-14 | 2018-01-16 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
US9827192B2 (en) | 2012-05-14 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9925203B2 (en) | 2012-05-14 | 2018-03-27 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US9669040B2 (en) | 2012-05-14 | 2017-06-06 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9867840B2 (en) | 2014-05-27 | 2018-01-16 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US20170095488A1 (en) * | 2012-05-14 | 2017-04-06 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9820999B2 (en) | 2012-05-14 | 2017-11-21 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US10016446B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone |
US9655908B2 (en) | 2012-05-14 | 2017-05-23 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
US9943531B2 (en) | 2014-08-08 | 2018-04-17 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US20170056427A1 (en) * | 2012-05-14 | 2017-03-02 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
US10039773B2 (en) | 2012-05-14 | 2018-08-07 | Antecip Bioventures Ii Llc | Neridronic acid for treating arthritis |
US10004756B2 (en) | 2014-05-15 | 2018-06-26 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10111837B2 (en) | 2012-05-14 | 2018-10-30 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds |
US9956238B2 (en) | 2014-05-15 | 2018-05-01 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US10173986B2 (en) | 2012-05-14 | 2019-01-08 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
US9861648B2 (en) | 2012-05-14 | 2018-01-09 | Antecip Boiventures Ii Llc | Osteoclast inhibitors for knee conditions |
US9827256B2 (en) | 2014-05-27 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating lower back pain |
US10028908B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9770457B2 (en) | 2012-05-14 | 2017-09-26 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesion |
US10350227B2 (en) | 2012-05-14 | 2019-07-16 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9616078B2 (en) | 2012-05-14 | 2017-04-11 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
US10016445B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US20170128472A1 (en) * | 2012-05-14 | 2017-05-11 | Antecip Bioventures Ii Llc | Administration of Zoledronic Acid to Treat Pain Associated with Ankylosing Spondylitis |
US20170071960A1 (en) * | 2012-05-14 | 2017-03-16 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US9707247B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US9707245B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US11654152B2 (en) | 2012-05-14 | 2023-05-23 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
US9999629B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9895383B2 (en) | 2012-05-14 | 2018-02-20 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10034890B2 (en) | 2012-05-14 | 2018-07-31 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US20170065625A1 (en) * | 2012-05-14 | 2017-03-09 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
US10463682B2 (en) | 2012-05-14 | 2019-11-05 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
US9211257B2 (en) | 2012-05-14 | 2015-12-15 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US9289441B2 (en) * | 2014-08-08 | 2016-03-22 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US9844559B2 (en) | 2012-05-14 | 2017-12-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesions |
CN102961785A (zh) * | 2012-11-09 | 2013-03-13 | 于秀淳 | 一种用于治疗骨巨细胞瘤的瘤腔填充物及其制备方法 |
US8859530B2 (en) | 2013-03-08 | 2014-10-14 | Voltarra Pharmaceuticals, Inc. | Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis |
US9012432B2 (en) * | 2013-03-08 | 2015-04-21 | Levolta Pharmaceuticals, Inc. | Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis |
KR20190009428A (ko) * | 2013-10-25 | 2019-01-28 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 질병의 치료를 위한, 졸레드론산 또는 관련 화합물의 경구 투여용 조성물 |
US9079927B1 (en) | 2014-05-27 | 2015-07-14 | Antecip Bioventures Ii Llc | Substituted imidazolium compounds for treating disease |
US9127069B1 (en) | 2014-06-11 | 2015-09-08 | Antecip Bioventures LLC | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
US9688765B2 (en) | 2014-06-11 | 2017-06-27 | Antecip Bioventures Ii Llc | Methods using RANK/RANKL antagonist antibodies for treating pain |
US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
CN107011380A (zh) * | 2016-01-28 | 2017-08-04 | 臧伟 | 一种二膦酸衍生物及含二膦酸衍生物的组合物治疗骨折的应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
US5358941A (en) * | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
FI92465C (fi) * | 1993-04-14 | 1994-11-25 | Risto Tapani Lehtinen | Menetelmä endo-osteaalisten materiaalien käsittelemiseksi |
US5646134A (en) * | 1994-04-21 | 1997-07-08 | Merck & Co., Inc. | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
TW390813B (en) * | 1994-04-29 | 2000-05-21 | Merck & Co Inc | Wet granulation formulation for bisphosphonic acids |
GB9408775D0 (en) * | 1994-05-04 | 1994-06-22 | Ciba Geigy Ag | Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration |
US6008206A (en) * | 1994-09-21 | 1999-12-28 | Merck & Co., Inc. | Sodium alendronate preparation for local administration |
JP3411690B2 (ja) * | 1994-09-21 | 2003-06-03 | 帝人株式会社 | 局所投与用アレンドロン酸ナトリウム製剤 |
US5652227A (en) * | 1995-01-30 | 1997-07-29 | Teronen; Olli Pekka | Inhibition of the degradation of connective tissue matrix protein components in mammals |
AU713824B2 (en) * | 1995-05-12 | 1999-12-09 | Merck Sharp & Dohme Corp. | Prevention of tooth loss by the administration of alendronate or its salts |
CA2241473A1 (en) * | 1997-06-26 | 1998-12-26 | Reese Products, Inc. | Trailer shipping container |
DE19731205A1 (de) * | 1997-07-21 | 1999-01-28 | Siemens Ag | Verfahren und Funk-Kommunikationssystem zur Informationsübertragung mittels ATM-Zellen |
US6015801A (en) * | 1997-07-22 | 2000-01-18 | Merck & Co., Inc. | Method for inhibiting bone resorption |
ATE353630T1 (de) * | 1998-11-12 | 2007-03-15 | Transave Inc | Inhalationssystem |
US6331533B1 (en) * | 1998-11-16 | 2001-12-18 | Merck & Co., Inc. | Method for inhibiting dental resorptive lesions |
DE10049404C2 (de) * | 2000-10-05 | 2003-01-30 | Fraunhofer Ges Forschung | Mit einem NIR-Marker versehener kunststoff-, glas-, textil- oder papierhaltiger Werkstoff und Verfahren zur Identifizierung dieses Werkstoffs |
-
2000
- 2000-11-29 GB GBGB0029111.2A patent/GB0029111D0/en not_active Ceased
-
2001
- 2001-11-27 NZ NZ525871A patent/NZ525871A/en not_active IP Right Cessation
- 2001-11-27 SK SK654-2003A patent/SK287501B6/sk not_active IP Right Cessation
- 2001-11-27 CA CA2427161A patent/CA2427161C/en not_active Expired - Fee Related
- 2001-11-27 US US10/432,847 patent/US20040063670A1/en not_active Abandoned
- 2001-11-27 DK DK01998352T patent/DK1339411T3/da active
- 2001-11-27 AT AT01998352T patent/ATE366112T1/de active
- 2001-11-27 JP JP2002545708A patent/JP2004514696A/ja active Pending
- 2001-11-27 WO PCT/EP2001/013836 patent/WO2002043738A2/en active IP Right Grant
- 2001-11-27 AU AU2002217061A patent/AU2002217061B2/en not_active Ceased
- 2001-11-27 CN CNA018197841A patent/CN1535152A/zh active Pending
- 2001-11-27 EP EP01998352A patent/EP1339411B1/en not_active Expired - Lifetime
- 2001-11-27 KR KR1020037005600A patent/KR100866025B1/ko not_active IP Right Cessation
- 2001-11-27 BR BR0115696-9A patent/BR0115696A/pt not_active Application Discontinuation
- 2001-11-27 CZ CZ20031467A patent/CZ301701B6/cs not_active IP Right Cessation
- 2001-11-27 PT PT01998352T patent/PT1339411E/pt unknown
- 2001-11-27 HU HU0302556A patent/HUP0302556A3/hu unknown
- 2001-11-27 KR KR1020087010650A patent/KR20080043409A/ko not_active Application Discontinuation
- 2001-11-27 IL IL15536301A patent/IL155363A0/xx active IP Right Grant
- 2001-11-27 ES ES01998352T patent/ES2287191T3/es not_active Expired - Lifetime
- 2001-11-27 RU RU2003117702/14A patent/RU2325913C2/ru not_active IP Right Cessation
- 2001-11-27 PL PL361774A patent/PL204001B1/pl unknown
- 2001-11-27 MX MXPA03004815A patent/MXPA03004815A/es not_active Application Discontinuation
- 2001-11-27 DE DE60129242T patent/DE60129242T2/de not_active Expired - Lifetime
- 2001-11-27 AU AU1706102A patent/AU1706102A/xx active Pending
- 2001-11-28 TW TW090129419A patent/TWI275393B/zh not_active IP Right Cessation
-
2003
- 2003-04-10 IL IL155363A patent/IL155363A/en not_active IP Right Cessation
- 2003-04-25 ZA ZA200303247A patent/ZA200303247B/en unknown
- 2003-05-27 NO NO20032405A patent/NO20032405D0/no not_active Application Discontinuation
-
2007
- 2007-09-07 CY CY20071101158T patent/CY1106851T1/el unknown
-
2008
- 2008-05-01 US US12/113,511 patent/US20080207565A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI275393B (en) | Use of bisphosphonates for pain treatment | |
RU2297229C2 (ru) | Фармацевтическое применение бисфосфонатов | |
JP5005188B2 (ja) | ビホスホネートの投与法 | |
AU2002257802A1 (en) | Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer | |
AU2002217061A1 (en) | Use of bisphosphonates for pain treatment | |
US20090209493A1 (en) | Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor | |
JP2006506365A (ja) | ビスホスホネートの投与方法 | |
US7345088B2 (en) | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol | |
AU2002363089A1 (en) | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a COX-2 inhibitor and a taxol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |